Carl Hansen, AbCellera CEO

As Omi­cron rages, FDA clears Eli Lil­ly/Ab­Celler­a's new an­ti­body days af­ter $720M sup­ply deal

The FDA has au­tho­rized a new Covid-19 an­ti­body from Eli Lil­ly and Ab­Cellera, adding a much-need­ed weapon to the ar­se­nal fight­ing against Omi­cron.

Just days ago, the two com­pa­nies un­veiled a $720 mil­lion deal to sup­ply 600,000 dos­es of the drug, bebtelovimab, to the US gov­ern­ment. It may now be pre­scribed, un­der emer­gency use au­tho­riza­tion, to adults and teenagers 12 or old­er with pos­i­tive SARS-CoV-2 tests who are ei­ther at high risk for pro­gres­sion to se­vere dis­ease or un­able/in­el­i­gi­ble for al­ter­na­tive treat­ment op­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.